2023
DOI: 10.1016/j.yebeh.2023.109435
|View full text |Cite
|
Sign up to set email alerts
|

The burden of chronic drug-refractory focal onset epilepsy: Can it be prevented?

Elinor Ben-Menachem,
Bettina Schmitz,
Reetta Kälviäinen
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 71 publications
0
1
0
Order By: Relevance
“…Epilepsy is estimated to affect 50-70 million people worldwide, with anti-seizure medications remaining the mainstay of treatment. Despite continued development of novel medications, an estimated 30-40% of patients with seizures develop drug-resistant epilepsy (DRE) [1][2][3]. DRE, as defined by the International League Against Epilepsy, is the "failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom" [4].…”
Section: Introductionmentioning
confidence: 99%
“…Epilepsy is estimated to affect 50-70 million people worldwide, with anti-seizure medications remaining the mainstay of treatment. Despite continued development of novel medications, an estimated 30-40% of patients with seizures develop drug-resistant epilepsy (DRE) [1][2][3]. DRE, as defined by the International League Against Epilepsy, is the "failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom" [4].…”
Section: Introductionmentioning
confidence: 99%